16 Dec
2020

Five key insights into 2020’s drug royalty transactions

Providing additional opportunities for the monetisation of life sciences IP, the drug royalty market continued to develop in 2020, producing a slew of new deals with creative and flexible structures

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth

TAGS

Market Developments, Non-Practising Entities, Patents, Strategy, Technology Licensing, Transactions, Valuation, Chemicals, Life Sciences, University & Research Institutions, Canada, Europe, International, North America, United States of America